Children now eligible for screening test for bacterium

(HealthDay) -- The U.S. Food and Drug Administration has expanded approval for a breath test that screens for a common ulcer-causing germ, to include children aged 3 years to 17.

The bacterium causes stomach inflammation (gastritis) and ulcers, and increases an infected person's risk of and a certain form of lymphoma. In a news release, the FDA said the BreathTak UBT test, approved for adults in 1996, is now sanctioned for children.

The U.S. Centers for Disease Control and Prevention estimates that more than two-thirds of the world's population is infected with the bacterium, abbreviated H. pylori, but most infected people never have symptoms, the FDA said.

The BreathTek UBT test was newly approved based on results from a multi-location clinical trial involving 176 children, the agency said.

The test is produced by Otsuka America Pharmaceutical, headquartered in Rockville, Md.

More information: To learn more about H. Pylori, visit the CDC.

add to favorites email to friend print save as pdf

Related Stories

Peptic ulcer bacterium alters the body's defense system

Jun 29, 2009

Helicobacter pylori survives in the body by manipulating important immune system cells. This is shown in a thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden. The discovery may lead to new treatm ...

Preventing gastric cancer with antibiotics

Mar 12, 2010

Helicobacter pylori, a bacterium found in about 50% of humans worldwide, can cause stomach ulcers and, in extreme cases, gastric cancer. In an article for F1000 Medicine Reports, Seiji Shiota and Yoshio Yamaoka discuss the p ...

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

9 hours ago

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

9 hours ago

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

10 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

10 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments